Literature DB >> 17039675

Diagnosis and management of hypersensitivity reactions caused by oxaliplatin.

T Herrero1, P Tornero, S Infante, V Fuentes, M N Sánchez, M De Barrio, M L Baeza.   

Abstract

Hypersensitivity reactions to oxaliplatin have been increasing since its introduction at the end of the 1990s, but allergy tests with antineoplastic drugs are rarely used to aid diagnosis. We describe 5 cases in which hypersensitivity reactions to oxaliplatin after several courses of chemotherapy were managed by allergy testing and desensitization. Skin prick tests were negative at 1 mg/mL in all patients, positive at 10 mg/mL in 2 tested patients, and negative in 10 control subjects. Intradermal tests were positive and not irritant at 0.01 to 0.001 mg/mL concentrations. A desensitization protocol with increasing concentrations and flow rates was successfully completed in all patients. We conclude that prick and intradermal skin tests are useful in the diagnosis of hypersensitivity reactions to oxaliplatin and that the desensitization protocol performed avoided discontinuation of chemotherapy in all patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039675

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  9 in total

Review 1.  Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.

Authors:  Joana Caiado; Matthieu Picard
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 2.  Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.

Authors:  Joana Caiado; Mariana Castells
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

3.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

Review 4.  Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes.

Authors:  Karen S Hsu Blatman; Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 5.  Hypersensitivity reactions to oxaliplatin and other antineoplastic agents.

Authors:  Ekaterini Syrigou; Kostas Syrigos; M Wasif Saif
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806

Review 6.  Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.

Authors:  Joana Caiado; Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2021-07-07       Impact factor: 4.806

7.  Effectiveness of oxaliplatin desensitization protocols.

Authors:  Susana Cortijo-Cascajares; Inmaculada Nacle-López; Ignacio García-Escobar; María José Aguilella-Vizcaíno; Alberto Herreros-de-Tejada; Hernán Cortés-Funes Castro; Miguel-Ángel Calleja-Hernández
Journal:  Clin Transl Oncol       Date:  2012-07-25       Impact factor: 3.405

Review 8.  Omalizumab for successful chemotherapy desensitisation: What we know so far.

Authors:  Roxana Silvia Bumbacea; Selda Ali; Sabina Loredana Corcea; Luiza Spiru; Cornelia Nitipir; Victor Strambu; Dragos Bumbacea
Journal:  Clin Transl Allergy       Date:  2021-12-13       Impact factor: 5.871

Review 9.  Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors:  Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal:  Exp Ther Med       Date:  2021-07-03       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.